Phoenix Children's Researcher Awarded $3 Million Grant to Develop New Therapy for Lung Diseases in Premature Babies
13 Feb 2024
PHOENIX, Feb. 13, 2024 /PRNewswire/ -- An internationally renowned research scientist at the Phoenix Children's Research Institute at the University of Arizona College of Medicine – Phoenix has been awarded a multimillion-dollar grant from the National Institutes of Health (NIH) to develop new treatment methods for lung disease in premature infants.
Continue Reading
Preview
Source: PRNewswire
Vladimir Kalinichenko, MD, PhD, Director for the Phoenix Children’s Research Institute at the University of Arizona College of Medicine – Phoenix, and professor of Child Health. Photo courtesy of Bruce Yeung Photography.
Vlad Kalinichenko, MD, PhD, director of the Research Institute and professor of Child Health with tenure, received $3 million from the National Heart, Lung and Blood Institute (NHLBI), the NIH's third-largest institute. His 20-year research career as principal investigator for NHLBI and other research foundations has centered on improving health outcomes for premature infants with respiratory conditions. Babies born prematurely often have underdeveloped lungs and may experience breathing problems or neonatal lung diseases that require long-term treatment or even lung transplantation.
"Medical advancements mean we can save babies at earlier gestational ages, but that means at times they're born before their lungs are fully developed, which comes with severe complications," Dr. Kalinichenko said. "This new funding allows us to explore new drugs, signaling mechanisms and targeted drug delivery systems, which can be used to develop innovative approaches for treatment of serious neonatal lung diseases."
Among the most severe complications for premature infants, bronchopulmonary dysplasia, or BPD, is a form of chronic lung disease that damages the lungs and airways, leading to difficulties in breathing due to low oxygenation rates in alveoli. The NHLBI grant will support the development of innovative treatments for BPD using gene therapy with a focus on nanoparticle-based deliveries that accelerate blood vessel formation. Research will also concentrate on cell therapy, particularly transplanting endothelial progenitor cells which line and protect blood vessels. For Dr. Kalinichenko and his team, the goal is to diversify approaches for treatments, especially in delivering therapeutic agents into premature lungs with high efficiency and precision.
The Phoenix Children's Research Institute at the University of Arizona College of Medicine – Phoenix launched in May 2023, formalizing a longstanding research collaboration between the health system and the UArizona College of Medicine – Phoenix. The Research Institute includes more than 700 active studies, 640 research investigators and 90 research staff members including research scientists, associates, biostatisticians, pharmacists, nurses and coordinators. Scientists engage in research across multiple clinical disciplines including cancer, neurology, cardiology, pulmonology and more.
About Phoenix Children's
Phoenix Children's is one of the nation's largest pediatric health systems. It comprises Phoenix Children's Hospital – Thomas Campus, Phoenix Children's Hospital – East Valley Campus, Phoenix Children's – Avondale Campus, Phoenix Children's – Arrowhead Campus, four pediatric specialty and urgent care centers, 11 community pediatric practices, 20 outpatient clinics, two ambulatory surgery centers and seven community-service outpatient clinics throughout the state of Arizona. The system provides world-class inpatient, outpatient, trauma, emergency and urgent care and has been serving children and families for 40 years. Phoenix Children's Care Network includes more than 1,175 pediatric primary care providers and specialists who deliver care across more than 75 subspecialties. Alongside our colleagues, collaborators and communities, we're elevating pediatric care, education and innovation, so we can all grow healthier together. For more information, visit phoenixchildrens.org.
SOURCE Phoenix Children's
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-Drugs
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.